Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

Inclusion Criteria

• •Performance status ≤1
• •Age ≥18 years and ≤ 75 years old
• •Histologically-confirmed adenocarcinoma of the prostate
• •Treated with continuous androgen ablative therapy (either surgical castration or LHRH agonist/antagonist) with documented castrate level of serum testosterone (\<50 ng/dl)
• •Metastatic disease radiographically documented by CT or bone scan
• •Patient must be HLA typed at high resolution using DNA based typing at the following loci: HLA-A, -B, -C, and DRB1
• •Patient must have available one or more potential first (biologic mother, sister, half-sister, or daughter) or second-degree related female donor. Mothers and daughters have a 100% chance of being haploidentical matches, sisters a 75% chance of being matched or haploidentical, and second degree relatives have a 50% chance of being haploidentical matches. The donor and recipient must be HLA identical for at least one antigen at HLA-A, -B, -C and HLA-DRB1.
• •Screening PSA must be ≥ 1.0 ng/mL.
• •Prior therapy with one second line hormonal therapy is allowed (i.e. bicalutamide, nilutamide, flutamide, ketoconazole, abiraterone, enzalutamide, ARN-509).
• •Prior docetaxel (≤ 6 cycles) as first line therapy
• •Cardiac ejection fraction at rest must be ≥ 40%
• •Acceptable liver function: Bilirubin \< 2.5 mg/dL (unless due to Gilbert's disease, AST (SGOT) and ALT (SGPT) \< 5 times upper limit of normal.
• •Acceptable renal function: Serum creatinine within normal range.
• •Pulmonary function: DLCO (corrected for hemoglobin), FEV1 and FVC \>50% predicted.
• •At least 4 wks since prior radiation or surgery with full recovery (no persistent toxicity ≥ Grade 1)
• •Ability to understand and willingness to sign a written informed consent document.